A prospective, randomized, controlled trial for the efficacy of baliximab induction combined with rapid steriod withdrawal in the blood-group compatible peditric liver transplantation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800019323

Enrollment

Unknown

Registered

2018-11-06

Start date

2018-11-20

Completion date

Unknown

Last updated

2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric liver transaplantation

Interventions

Group 1:Barriximab induction

Group 2:Sreriod therapy 6 month

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children conducted liver transplantation less than 72 months; be the first liver transplantation.

Exclusion criteria

Exclusion criteria: Donor and recipient blood type incompatibility, multiple organ transplantation, retransplantation, previous immunomodulatory treatment

Design outcomes

Primary

Measure	Time frame
survival rate of recipients;survival rate of grafts;incidence and severity of rejection of recipients;incidence of infection;	—

Secondary

Measure	Time frame
New disease situation;Growth and development;	—

Countries

China

Contacts

Public ContactWei Gao

Tianjin First Central Hospital

gao-wei@medmail.com.cn+86 13920128996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026